|Videos|July 23, 2013
Episode 6 - Addressing the Gaps in Care for Hemophilia Patients
Advertisement
Delivering the optimal care to patients with hemophilia is often a challenge, both clinically and financially. According to Patrick Fogarty, MD, the individuals who are best fit to execute treatment guidelines are those who practice at specialty hemophilia treatment centers, as they are able to provide on-site multidisciplinary, comprehensive care.
However, the panelists conclude that there are still gaps in current treatment guidelines that require addressing. In an effort to provide the best of care to all patients with hemophilia, regardless of geography, strategies such as home care, satellite clinics, and increased patient education have been implemented into contemporary treatment paradigms.
Advertisement
Related to this article
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
4
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
5